| Outcome Measures: |
Primary: Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery, Mean of the HbA1c data collected at gestational week (GW) corresponding to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact. On-treatment observation period started at the date of first dose of trial product and ended at the date of the last day on trial product, up to 22 months., From GW 16 to GW 36 | Secondary: Number of Participants With HbA1c Below or Equal to 6.0% [42 Millimoles Per Mole (mmol/Mol)] From Last Planned HbA1c Prior to Delivery (Yes/no), Number of participants who achieved pre-defined HbA1c targets ≤ 6.0% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.0% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.0% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., From GW 16 to GW 36|Number of Participants With HbA1c Below or Equal to 6.5% (48 mmol/Mol) From Last Planned HbA1c Prior to Delivery (Yes/no), Number of participants who achieved pre-defined HbA1c targets ≤ 6.5% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.5% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.5% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., From GW 16 to GW 36|Last Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals), Mean of post-prandial glucose (PPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. Average PPG is defined as the average of the available blood glucouse (BG) measurements 90 minutes after breakfast, lunch and main evening meal respectively. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., From GW 16 to GW 36|Last Planned Fasting Plasma Glucose Prior to Delivery, Mean of fasting plasma glucose (FPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from in-trial observation period. The in-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., From GW 16 to GW 36|Number of Hypoglycaemic Episodes During the Pregnancy Period, Number of treatment emergent hypoglycaemic episodes during the pregnancy period is presented. Hypoglycaemic episode (plasma glucose \<= 3.9 mmol/L (70 milligrams per decilitre (mg/dL)) Or \> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode occurs on or after the first day of trial product administration, and no later than 7 days from the last day on trial product. The endpoint was evaluated based on the data from pregnancy period. Pregnancy period started from first day of pregnancy (date of conception corresponding to the first day in GW 2) or randomisation (whichever comes last) to the date of delivery., From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)|Number of Participants Who Developed Sight-threatening Retinopathy (Defined as Proliferative Retinopathy or Maculopathy) From Pregnancy Baseline to the End of Treatment (Yes/no), Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. Eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between pregnancy baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy., From pregnancy baseline (corresponding to GW 8-13) to end of treatment (28 days after delivery)|Number of Participants Who Developed Sight-threatening Retinopathy Defined as Proliferative Retinopathy or Maculopathy From Treatment Baseline to the End of Treatment (Yes/no), Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. For pregnant women, eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between treatment baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy., From treatment baseline (week 0) to end of treatment (28 days after delivery)|Number of Adverse Events During Pregnancy Period, Number of adverse events (AEs) during pregnancy period is reported. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs presented are treatment-emergent AEs (TEAEs). The TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment., From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)|Number of Participants With Pre-eclampsia Defined as New-onset Hypertension Occurring From Gestational Week 20 to Delivery and Simultaneous Proteinuria or Presence of Eclampsia, HELLP Syndrome, or Other Severe Organ Involvement (Yes/no), Number of participants with one or more events of pre-eclampsia during pregnancy period is reported. Pre-eclampsia was defined as new-onset hypertension (greater than or equal to) ≥ 140 millimeters of mercury (mmHg) systolic or ≥ 90 mmHg diastolic, based on at least 2 measurements taken at least 4 hours apart) occurring from GW 20 to delivery and simultaneous proteinuria (defined as ≥ 300 mg protein in a 24 hours urine sample, a protein-to-creatinine ratio of ≥ 300 mg/g in a urine sample or a urine dipstick protein of 1+) or presence of eclampsia, haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, or other severe organ involvement. In the reported data, 'Yes' infers number of participants who had pre-eclampsia events whereas 'No' infers number of participants who have not had pre-eclampsia events., From GW 20 to delivery|Number of Participants With Different Modes of Delivery e.g. Vaginal, Operative Vaginal, Planned Caesarean Section or Unplanned Caesarean Section Delivery, Number of participants who had delivered by which mode of delivery (vaginal, operative vaginal, planned caesarean section or unplanned caesarean section delivery) is presented. Planned caesarean section: decision taken \> 8 hours prior to delivery. Unplanned caesarean section: decision taken ≤ 8 hours prior to delivery. In case of 'early foetal death' or if the participant did not fill the pregnancy outcome form then mode of delivery was reported as 'missing'., At birth|Change in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery, Change in body weight from pregnancy baseline to last planned visit prior to delivery is presented., From pregnancy baseline (corresponding to gestational week 8-13) to last planned visit before delivery (last weight recording before given birth)|Birth Weight for Live Birth Infants, Mean birth weight for live birth infants is presented. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., At birth|Birth Weight Standard Deviation (SD) Score for Live Birth Infants, Mean of birth weight SD score for live infants is presented. Birth weight SD score indicates how far an infant's score deviates from the mean of the reference population of same age and same sex born at the same gestational week as per local normal curves. The SD score of 0 indicates that the infants born weigh approximately the same, negative score indicates that the infants born weigh lesser and positive score indicates that the infants born weigh more when compared with the reference population. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., At birth|Number of Live Born Infants With Birth Weight < 10th Percentile for Gestational Age and Sex (Local References) (Yes/no), Number of live born infants with birth weight \<10th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants.In the reported data,'Yes' infers number of live born infants with birth weight \<10th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \<10th percentile for gestational age and sex.Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form.Endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion,up to 24 months.Date of trial completion:final scheduled follow-up visit (delivery + 58 days)., At birth|Number of Live Born Infants With Birth Weight > 90th Percentile for Gestational Age and Sex (Local References) [Yes/no], Number of live born infants with birth weight \>90th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants. In the reported data,'Yes' infers number of live born infants with birth weight \>90th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \>90th percentile for gestational age and sex.Unaddressed category refers to cases where either parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if THE participants did not fill the pregnancy outcome form.The endpoint was evaluated based on the data from in-trial observation period:started at randomization and ended at the date of trial completion,up to 24 months. Date of trial completion:final scheduled follow-up visit (delivery + 58 days)., At birth|Number of Participants With Pre-term Delivery, Number of pregnant women who had pre-term delivery is presented. Pre-term delivery refers to delivery in \< 37 completed GWs. In the reported data, 'Yes' infers number of participants who had pre-term delivery whereas 'No' infers number of participants who has not had pre-term delivery. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion,up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery+58 days). For participants who had not attended the follow-up visit,the date of trial completion was the date of the last participant-investigator contact., At birth|Number of Participants With Early Foetal Death (Delivery Before 20 Completed GWs) (Yes/no), Number of participants who had early foetal death (delivery before 20 completed GWs) is presented. In the reported data, 'Yes' infers early foetal deaths whereas 'No' infers no foetal deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., At birth|Number of Participants Who Had Perinatal Mortality (Death of Foetus/Infant ) (Yes/no), Number of participants who had foetal/infant loss at delivery is presented. Perinatal mortality: death of foetus/infant between ≥ 20 completed GWs before delivery and \<1 completed week after delivery). In the reported data, 'Yes' infers early foetal/infant deaths whereas 'No' infers no foetal/infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion, up to 24 months. Date of trial completion: final scheduled follow-up visit (delivery + 58 days)., Between at least 20 completed GWs before delivery and before 7 completed days after delivery|Number of Participants Who Had Neonatal Mortality (Death of Infant) (Yes/no), Number of participants who had infant loss after delivery is presented. Neonatal mortality: death of infant between ≥7 completed days after delivery and \< 28 completed days after delivery. In the reported data, 'Yes' infers infant deaths whereas 'No' infers no infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., Between at least 7 completed days after delivery and before 28 completed days after delivery|Number of Participants With Presence of Major Abnormalities (Classified According to European Concerted Action on Congenital Anomalies and Twins (EUROCAT)) in Their Foetus/Infants, Number of participants who delivered foetuses/infants with abnormalities (classified according to EUROCAT) is presented. Presence of major abnormalities were based on adjudicated data, as after adjudication congenital anomalies were classified into major or minor anomalies or in other categories. In reported data, 'Yes' infers presence of major abnormalities whereas 'No' infers absence of major abnormalities in foetus/infant. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion up to 24 months. Date of trial completion : final scheduled follow-up visit (delivery + 58 days)., At birth|Number of Participants With Live Born Infants (Yes/no), Number of participants with live born infants is presented. In the reported data, 'Yes' infers number of live infants whereas 'No' infers early foetal death or termination of pregnancy (induced/elective abortion). The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact., At birth|Number of Adverse Events in the Infant, AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AEs in foetus/infant with particular focus on the AEs from delivery to follow-up are presented., From delivery to final follow-up 30 days after delivery|Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no), Number of infants with neonatal hypoglycaemic episodes is presented. Neonatal hypoglycaemic episodes defined as plasma glucose ≤ 1.7 mmol/L (31 mg/dL) during the first 24 hours after birth or below or equal to 2.5 mmol/L (45 mg/dl) between 24 hours and 48 hours after birth. In the reported data, 'Yes' infers number of infants with neonatal hypoglycaemic episodes whereas 'No' infers number of infants with no neonatal hypoglycaemic episodes. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form., During between 24 and 48 hours after birth
|
| Locations: |
Novo Nordisk Investigational Site, Caba, C1180AAX, Argentina|Novo Nordisk Investigational Site, Caba, C1189AAS, Argentina|Novo Nordisk Investigational Site, Caba, C1430CKE, Argentina|Novo Nordisk Investigational Site, Córdoba, X5016KEH, Argentina|Novo Nordisk Investigational Site, Mendoza, 5500, Argentina|Novo Nordisk Investigational Site, Salta, 4400, Argentina|Novo Nordisk Investigational Site, Blacktown, New South Wales, 2148, Australia|Novo Nordisk Investigational Site, Campbelltown, New South Wales, 2560, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, 2065, Australia|Novo Nordisk Investigational Site, Ipswich, Queensland, 4305, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, 5112, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, 3128, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, 3052, Australia|Novo Nordisk Investigational Site, Graz, 8036, Austria|Novo Nordisk Investigational Site, Innsbruck, 6020, Austria|Novo Nordisk Investigational Site, Wien, 1090, Austria|Novo Nordisk Investigational Site, Wien, 1130, Austria|Novo Nordisk Investigational Site, Wien, A 1170, Austria|Novo Nordisk Investigational Site, Goiânia, Goias, 74605-020, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, 80030-110, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, 90430-001, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, 01228-200, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, 05403-000, Brazil|Novo Nordisk Investigational Site, Ribeirao Preto, 14049-900, Brazil|Novo Nordisk Investigational Site, Edmonton, Alberta, T6G 2E1, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novo Nordisk Investigational Site, St John's, Newfoundland and Labrador, A1B 3V6, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, B3K 6R8, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, N1R 7L6, Canada|Novo Nordisk Investigational Site, London, Ontario, N6G 2V4, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M4N 3M5, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M5T 3L9, Canada|Novo Nordisk Investigational Site, PQ, Quebec, G1L 3L5, Canada|Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Aarhus N, 8200, Denmark|Novo Nordisk Investigational Site, København ø, 2100, Denmark|Novo Nordisk Investigational Site, Athens, 11521, Greece|Novo Nordisk Investigational Site, Athens, GR-11528, Greece|Novo Nordisk Investigational Site, Larissa, GR-41110, Greece|Novo Nordisk Investigational Site, Nea Efkarpia - Thessaloniki, GR-56403, Greece|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 7, Ireland|Novo Nordisk Investigational Site, Galway, H91 YR71, Ireland|Novo Nordisk Investigational Site, Petach Tikva, 49100, Israel|Novo Nordisk Investigational Site, Rehovot, 76100, Israel|Novo Nordisk Investigational Site, Milano, 20122, Italy|Novo Nordisk Investigational Site, Milano, 20132, Italy|Novo Nordisk Investigational Site, Padova, 35143, Italy|Novo Nordisk Investigational Site, Roma, 00189, Italy|Novo Nordisk Investigational Site, Sant'Andrea Delle Fratte (PG), 06129, Italy|Novo Nordisk Investigational Site, Torino, 10126, Italy|Novo Nordisk Investigational Site, Ekaterinburg, 620028, Russian Federation|Novo Nordisk Investigational Site, Kirov, 610014, Russian Federation|Novo Nordisk Investigational Site, Moscow, 101000, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 199034, Russian Federation|Novo Nordisk Investigational Site, Saratov, 410039, Russian Federation|Novo Nordisk Investigational Site, Tomsk, 634050, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, 432063, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, 424004, Russian Federation|Novo Nordisk Investigational Site, Belgrade, 11000, Serbia|Novo Nordisk Investigational Site, Barcelona, 08025, Spain|Novo Nordisk Investigational Site, Bath, BA1 3NG, United Kingdom|Novo Nordisk Investigational Site, Bradford, BD9 6RJ, United Kingdom|Novo Nordisk Investigational Site, Cambridge, CB2 2QQ, United Kingdom|Novo Nordisk Investigational Site, High Wycombe, HP11 2TT, United Kingdom|Novo Nordisk Investigational Site, Leeds, LS9 7TF, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, TS4 3BW, United Kingdom|Novo Nordisk Investigational Site, Norwich, NR4 7UQ, United Kingdom|Novo Nordisk Investigational Site, Nottingham, NG7 2UH, United Kingdom|Novo Nordisk Investigational Site, Oxford, OX3 7LE, United Kingdom|Novo Nordisk Investigational Site, Truro, TR1 3LJ, United Kingdom
|
